Asthma Clinical Trial Landscape
Data updated: May 20, 2026
1,419 clinical trials tracked since 2008
Asthma is a chronic respiratory disease characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing, coughing, and shortness of breath. It affects millions worldwide, impacting both children and adults. The clinical trial landscape for asthma is active, with 1,415 trials registered since 2008, including 177 currently active trials that are recruiting, enrolling, or active but not recruiting. Activity is distributed across all phases, with 76 active Phase 2 trials representing the largest segment, followed by 53 active Phase 3 trials, 36 active Phase 4 trials, and 22 active Phase 1 trials. Industry sponsorship is led by AstraZeneca, which has 15 active trials. GSK follows with 7 active trials, and Sanofi with 5. Guangdong Hengrui Pharmaceutical Co., Ltd and Inmunotek S.L. each have 4 active trials. The relatively high number of active Phase 2 trials suggests a strong focus on evaluating the efficacy and safety of new treatments in mid-stage development.
179 active
/
1419 total (since 2008)
23
Phase 1 Active
320 total
79
Phase 2 Active
539 total
53
Phase 3 Active
382 total
34
Phase 4 Active
247 total
Top Industry Sponsors
Sorted by active Active Done Failed
AstraZeneca 15 112 7
GSK 7 140 11
Sanofi 5 18 0
Guangdong Hengrui Pharmaceutical Co., Ltd 4 1 0
Inmunotek S.L. 4 0 0
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT06750289 RECRUITING
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
AstraZeneca n=400
NCT06664619 RECRUITING
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Teva Branded Pharmaceutical Products R&D LLC n=724
NCT06465485 ACTIVE NOT RECRUITING
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
AstraZeneca n=504
NCT05692180 RECRUITING
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
AstraZeneca n=200
NCT05562466 RECRUITING
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
Novartis Pharmaceuticals n=200
+ 377 more Phase 3 trials — see full database below
Asthma — Trials Started by Year (last 10 years)
2016 69
2017 75
2018 58
2019 62
2020 34
2021 66
2022 57
2023 48
2024 66
2025 56
2026 32
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
AstraZeneca 134
GSK 158
Sanofi 23
Guangdong Hengrui Pharmaceutical Co., Ltd 5
Inmunotek S.L. 4
Novartis 71
Generate Biomedicines 3
Chiesi Farmaceutici S.p.A. 50
Amgen 11
Anhui Palo Alto Pharmaceuticals, Inc. 3
Active Trials by Phase
Phase 1 23
Phase 2 79
Phase 3 53
Phase 4 34
Enrollment Size Distribution
1-50 526
51-200 413
201-500 234
501-1k 110
1k+ 70
All Industry Sponsors
Sorted by active Active Done Failed
AstraZeneca 15 112 7
GSK 7 140 11
Sanofi 5 18 0
Guangdong Hengrui Pharmaceutical Co., Ltd 4 1 0
Inmunotek S.L. 4 0 0
Novartis 3 51 17
Generate Biomedicines 3 0 0
Chiesi Farmaceutici S.p.A. 2 43 5
Amgen 2 6 3
Anhui Palo Alto Pharmaceuticals, Inc. 2 1 0
Teva Branded Pharmaceutical Products R&D LLC 2 0 0
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 2 0 0
Oneness Biotech Co., Ltd. 2 0 0
Shanghai Mabgeek Biotech.Co.Ltd 2 0 0
Haisco Pharmaceutical Group Co., Ltd. 2 0 0
NCT06750289 RECRUITING
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
AstraZeneca n=400
NCT06664619 RECRUITING
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Teva Branded Pharmaceutical Products R&D LLC n=724
NCT06465485 ACTIVE NOT RECRUITING
STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
AstraZeneca n=504
NCT05692180 RECRUITING
A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)
AstraZeneca n=200
NCT05562466 RECRUITING
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
Novartis Pharmaceuticals n=200
NCT06052267 RECRUITING
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
Teva Branded Pharmaceutical Products R&D LLC n=2,700
NCT06307665 RECRUITING
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca n=440
NCT06023589 RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
AstraZeneca n=231
NCT07372287 RECRUITING
A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. n=230
NCT07276724 RECRUITING
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
Generate Biomedicines n=786
NCT07546981 NOT YET RECRUITING
Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists
Chiesi Farmaceutici S.p.A. n=554
NCT07363642 RECRUITING
Phase 3b Study in Patients With Severe Asthma Treated With Tezepelumab
AstraZeneca n=400
NCT04699604 RECRUITING
A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
Bridgette Jones n=300
NCT06471257 RECRUITING
A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma
AstraZeneca n=790
NCT07359846 RECRUITING
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Generate Biomedicines n=786
NCT07444567 NOT YET RECRUITING
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
AstraZeneca n=230
NCT06488755 RECRUITING
SIM0718 Treatment of Asthma Clinical Study
Simcere Pharmaceutical Co., Ltd n=418
NCT06191315 RECRUITING
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
Sanofi n=90
NCT06473779 ACTIVE NOT RECRUITING
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
AstraZeneca n=326
NCT07456033 NOT YET RECRUITING
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
GlaxoSmithKline n=456
NCT07309614 RECRUITING
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Université de Sherbrooke n=150
NCT06502366 ACTIVE NOT RECRUITING
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
AstraZeneca n=422
NCT05776927 NOT YET RECRUITING
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
Novartis Pharmaceuticals n=304
NCT06323213 RECRUITING
Efficacy and Safety Study of 610 in Patients With Severe Asthma
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. n=480
NCT07318350 NOT YET RECRUITING
Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA)
Eurofarma Laboratorios S.A. n=174
NCT07302516 NOT YET RECRUITING
Compare the Efficacy and Safety of QL2302 Versus Tezspire® in Severe Asthma
Qilu Pharmaceutical Co., Ltd. n=636
NCT06223828 RECRUITING
Azithromycin for Critical Asthma - Pediatrics
Johns Hopkins All Children's Hospital n=100
NCT06653322 RECRUITING
A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
Guangdong Hengrui Pharmaceutical Co., Ltd n=400
NCT05757102 RECRUITING
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
GlaxoSmithKline n=292
NCT06570889 RECRUITING
VItamin D in pregnanCy for prevenTion Of eaRlY Childhood Asthma
Professor Klaus Bønnelykke n=2,000
NCT06560255 RECRUITING
Fish Oil in pREgnancY for Personalized Prevention of Early Childhood Asthma
Professor Klaus Bønnelykke n=2,000
NCT07098403 RECRUITING
A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma
Guangdong Hengrui Pharmaceutical Co., Ltd n=408
NCT05748600 ACTIVE NOT RECRUITING
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma
Areteia Therapeutics n=600
NCT04651777 ACTIVE NOT RECRUITING
Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma
Dr. Grace Parraga n=31
NCT06721247 ACTIVE NOT RECRUITING
Oral Intake of Mg in Controlled Asthmatic Patients
Zagazig University n=166
NCT05251402 ACTIVE NOT RECRUITING
Addressing Quality of Life, Clinical Outcomes, and Mechanisms in Uncontrolled Asthma Following the DASH Dietary Pattern
University of Illinois at Chicago n=323
NCT07013123 NOT YET RECRUITING
Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
University Hospital, Montpellier n=38
NCT06895460 NOT YET RECRUITING
A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets)
The First Affiliated Hospital with Nanjing Medical University n=198
NCT04898283 RECRUITING
Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
Inmunotek S.L. n=180
NCT04435990 RECRUITING
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
Inmunotek S.L. n=150
NCT04891237 RECRUITING
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Inmunotek S.L. n=180
NCT06955559 NOT YET RECRUITING
Magnesium Sulfate in Bronchial Asthma and Acute Bronchiolitis in Children
Assiut University n=60
NCT06837922 RECRUITING
Clinical Trial of MG-K10 in Stage III of Moderate to Severe Asthma
Shanghai Mabgeek Biotech.Co.Ltd n=504
NCT06829784 RECRUITING
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. n=660
NCT06740045 NOT YET RECRUITING
Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe Asthma
Dr. Andrew Thamboo, MD n=10
NCT06618105 NOT YET RECRUITING
Bronchoprovocation Study to Demonstrate the Pharmacodynamic Bioequivalence of Albuterol Sulfate HFA Inhalation Aerosol (E.Q. 90 mcg of Albuterol Base/Inh) of Macleods Pharmaceuticals Ltd
Macleods Pharmaceuticals Ltd n=144
NCT05761028 RECRUITING
A Study of CM310 in Subjects With Moderate to Severe Asthma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=600
NCT05641272 NOT YET RECRUITING
Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract
Inmunotek S.L. n=90
NCT03667651 ACTIVE NOT RECRUITING
The PEBBLES Study - Testing a Strategy for Preventing Eczema and Food Allergy in High Risk Infants
University of Melbourne n=760
NCT00920621 COMPLETED
Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART)
Brigham and Women's Hospital n=876
NCT00861926 COMPLETED
Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2)
Chiesi Farmaceutici S.p.A. n=1,714
NCT06264674 COMPLETED
Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).
Chiesi Farmaceutici S.p.A. n=827
NCT04886999 COMPLETED
Study in Adult Patients With Moderate to Severe Asthma
Chiesi Farmaceutici S.p.A. n=78
NCT01577082 COMPLETED
Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients
Chiesi Farmaceutici S.p.A. n=542
NCT06261957 COMPLETED
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
GlaxoSmithKline n=477
NCT05850494 COMPLETED
Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma
AstraZeneca n=52
NCT05202262 COMPLETED
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
AstraZeneca n=645
NCT05755906 COMPLETED
A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS)
AstraZeneca n=374
NCT05555290 COMPLETED
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
AstraZeneca n=190
NCT05243680 COMPLETED
An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)
GlaxoSmithKline n=641
NCT03226392 COMPLETED
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Novartis Pharmaceuticals n=704
NCT03215758 COMPLETED
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Novartis Pharmaceuticals n=675
NCT02892344 COMPLETED
Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma
Novartis Pharmaceuticals n=802
NCT05280418 COMPLETED
Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma
McMaster University n=27
NCT05735431 WITHDRAWN
Non-Inferiority,Combination Formoterol/FluticasonexAlenia®Formoterol/Budesonide for Asthma in Brazil
Eurofarma Laboratorios S.A.
NCT05813288 TERMINATED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
Areteia Therapeutics n=654
NCT06388889 TERMINATED
Phase III Long-Term Extension Study With Dexpramipexole
Areteia Therapeutics n=509
NCT05763121 TERMINATED
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
Areteia Therapeutics n=1,061
NCT05274815 COMPLETED
Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
AstraZeneca n=305
NCT03560466 COMPLETED
Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)
Sanofi n=378
NCT04718389 COMPLETED
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
GlaxoSmithKline n=1,717
NCT03015610 COMPLETED
Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma
Jason Lang, M.D., M.P.H. n=41
NCT05292586 COMPLETED
A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid
Chiesi Farmaceutici S.p.A. n=1,377
NCT06245551 COMPLETED
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
AstraZeneca n=64
NCT05191186 COMPLETED
Documentation of Efficacy of Intralymphatic Allergen Immunotherapy
Aarhus University Hospital n=450
NCT04937387 COMPLETED
Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma
GlaxoSmithKline n=359
NCT05505734 COMPLETED
A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma
Bond Avillion 2 Development LP n=2,516
NCT06154304 COMPLETED
BE Study of Albuterol Sulfate Inhalation Aerosol 90 mcg Per Actuation in Patients With Stable Mild Asthma
Cipla Ltd. n=120
NCT03927157 COMPLETED
Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
AstraZeneca n=405
NCT03248128 COMPLETED
Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma
GlaxoSmithKline n=906
NCT03365687 COMPLETED
Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers
Professor Francine Ducharme n=323
NCT01167010 COMPLETED
A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma
Eurofarma Laboratorios S.A. n=552
NCT04609904 COMPLETED
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)
AstraZeneca n=2,187
NCT04609878 COMPLETED
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
AstraZeneca n=2,274
NCT05398263 TERMINATED
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
AstraZeneca n=125
NCT01202097 COMPLETED
A Non- Inferiority Comparative Study Between Seretide® and Salmeterol/Fluticasone Eurofarma in Patients with Asthma
Eurofarma Laboratorios S.A. n=334
NCT06869798 COMPLETED
EFFECTIVENESS OF ZINC AS AN ADJUVANT TO STANDARD THERAPY VERSUS STANDARD THERAPY ALONE IN CHILDREN
King Edward Medical University n=84
NCT01001364 COMPLETED
A Comparative Study Between Foraseq and Formoterol/Budesonide Inhalation Capsules in Patients with Asthma
Eurofarma Laboratorios S.A. n=88
NCT04669288 TERMINATED
AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department
University of Arizona n=840
NCT04233190 COMPLETED
A Multicenter, Randomized, Parallel, Two-period, Non-inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment
Eurofarma Laboratorios S.A. n=472
NCT04719832 COMPLETED
Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
GlaxoSmithKline n=395
NCT02197702 COMPLETED
Vitamin D in Preschoolers With Viral-induced Asthma
St. Justine's Hospital n=47
NCT04718103 COMPLETED
A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype
GlaxoSmithKline n=397
NCT06657066 COMPLETED
EFFECTIVENESS of PROBIOTICS in ADULTS with MODERATE to SEVERE PERSISTENT ASTHMA
King Edward Medical University n=74
NCT06626620 COMPLETED
Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma
Muhammad Aamir Latif n=120
NCT03562195 COMPLETED
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
GlaxoSmithKline n=300
NCT06461949 WITHDRAWN
Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
National Institute on Deafness and Other Communication Disorders (NIDCD)
NCT01566149 COMPLETED
Study of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI) in Adolescents & Adults With Persistent Asthma (P08212)
Organon and Co n=49
NCT03000413 COMPLETED
Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial
Hospital Nossa Senhora da Conceicao n=45
NCT00599027 COMPLETED
An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma
Organon and Co n=51
NCT00604500 COMPLETED
A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
Organon and Co n=272
NCT02741271 COMPLETED
Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)
Organon and Co n=181
NCT03186209 COMPLETED
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
AstraZeneca n=695
NCT02062463 COMPLETED
Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=485
NCT03137303 COMPLETED
Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)
University of Illinois at Chicago n=402
NCT03341403 COMPLETED
Effect of a Synbiotic "Probiotical®/Bactecal® " in Asthma
University of Liege n=55
NCT01803555 COMPLETED
Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®
Teva Branded Pharmaceutical Products R&D, Inc. n=605
NCT03453112 COMPLETED
Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.
Chiesi Farmaceutici S.p.A. n=494
NCT01484210 COMPLETED
Single Dose Study of the Fluticasone/Salmeterol (500/50 μg) Administered With Elpenhaler® Versus Diskus®
Elpen Pharmaceutical Co. Inc. n=28
NCT01027143 COMPLETED
Obesity and Asthma: Nutrigenetic Response to Omega-3 Fatty Acids
Nemours Children's Clinic n=143
NCT05322707 COMPLETED
BE Study Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg Inhalation Product in Asthma Patient
Cipla Ltd. n=1,485
NCT04705727 TERMINATED
Budesonide/Formoterol Turbuhaler® Versus Terbutaline Nebulization as Reliever Therapy in Children With Moderate Asthma Exacerbation
Centre Hospitalier Intercommunal Creteil n=102
NCT01691859 COMPLETED
MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
GlaxoSmithKline n=347
NCT05062759 COMPLETED
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
AstraZeneca n=70
NCT03557307 COMPLETED
Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
AstraZeneca n=598
NCT03706079 COMPLETED
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
AstraZeneca n=951
NCT04305405 COMPLETED
PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma
AstraZeneca n=30
NCT05813470 COMPLETED
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
Cinnagen n=256
NCT03847896 COMPLETED
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma
Bond Avillion 2 Development LP n=1,001
NCT04665895 COMPLETED
A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma
Respirent Pharmaceuticals Co Ltd. n=451
NCT04265105 COMPLETED
Fluticasone-Vilanterol Once Daily Dose for the Treatment of Mild Asthma in Adults
Royal College of Surgeons in Ireland - Medical University of Bahrain n=18
NCT02192827 COMPLETED
Use of Dexamethasone in Pediatric Asthma Exacerbations
University at Buffalo n=318
NCT03620747 COMPLETED
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
Sanofi n=393
NCT03884842 COMPLETED
Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma.
McMaster University n=24
NCT03470311 COMPLETED
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies
McMaster University n=20
NCT04259164 COMPLETED
Anti-inflammatory Effects Glycopyrronium
University Medical Center Groningen n=28
NCT03782532 COMPLETED
Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma
Sanofi n=486
NCT03052725 TERMINATED
A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=391
NCT03769090 COMPLETED
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
Bond Avillion 2 Development LP n=3,132
NCT03015259 COMPLETED
Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients
Kindeva Drug Delivery n=1,762
NCT04215848 COMPLETED
As-needed Budesonide/Formoterol Turbuhaler in Stepping Down Period
Hat Yai Medical Education Center n=31
NCT04048343 COMPLETED
Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma
AstraZeneca n=65
NCT05292976 WITHDRAWN
Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation
Aurobindo Pharma Ltd
NCT04049175 TERMINATED
Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma
Chiesi Farmaceutici S.p.A. n=810
NCT02134028 COMPLETED
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
Sanofi n=2,282
NCT02245672 COMPLETED
MGR001 / Advair Diskus Local Equivalence Study in Asthma
Mylan Pharma UK Ltd. n=1,128
NCT01026870 WITHDRAWN
Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115)
Organon and Co
NCT04206761 WITHDRAWN
Investigating the Effects of QVM149 on MRI Ventilation Defects
Dr. Grace Parraga
NCT03406078 COMPLETED
Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
AstraZeneca n=150
NCT03347279 COMPLETED
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
AstraZeneca n=1,061
NCT02139644 COMPLETED
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=787
NCT02141854 COMPLETED
Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=882
NCT02031640 COMPLETED
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=1,113
NCT01287039 COMPLETED
A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=489
NCT02513160 COMPLETED
Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=713
NCT02969408 COMPLETED
A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=397
NCT02501629 COMPLETED
An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
Teva Branded Pharmaceutical Products R&D, Inc. n=177
NCT02040779 COMPLETED
A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=273
NCT02040766 COMPLETED
A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=628
NCT02175771 COMPLETED
Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=758
NCT02980133 COMPLETED
Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler
Teva Branded Pharmaceutical Products R&D, Inc. n=841
NCT02452190 COMPLETED
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
Teva Branded Pharmaceutical Products R&D, Inc. n=468
NCT02126839 COMPLETED
A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics
Teva Branded Pharmaceutical Products R&D, Inc. n=186
NCT01285323 COMPLETED
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=464
NCT03170271 COMPLETED
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
AstraZeneca n=660
NCT03468790 COMPLETED
Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.
Shanghai Biomabs Pharmaceutical Co., Ltd. n=393
NCT03629249 TERMINATED
Systemic Corticosteroids Avoidance Study in Severe Asthma Patients
Novartis Pharmaceuticals n=604
NCT03158311 COMPLETED
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
Novartis Pharmaceuticals n=1,426
NCT03756883 COMPLETED
Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma
Actavis Inc. n=999
NCT03879837 COMPLETED
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
Actavis Inc. n=1,902
NCT01392859 COMPLETED
Characterization of the Role of Histamine in Children With Asthma
Children's Mercy Hospital Kansas City n=211
NCT02563067 COMPLETED
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
Novartis Pharmaceuticals n=877
NCT02808819 COMPLETED
A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist
AstraZeneca n=447
NCT02676089 COMPLETED
TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)
Chiesi Farmaceutici S.p.A. n=1,433
NCT02676076 COMPLETED
TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA
Chiesi Farmaceutici S.p.A. n=1,153
NCT02924688 COMPLETED
A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma
GlaxoSmithKline n=2,436
NCT01449162 COMPLETED
Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids
AB Science n=420
NCT04124510 TERMINATED
Efficacy and Safety of Flutiform K-haler in Patients With Uncontrolled Asthma Following Mid-dose ICS/LABA DPI Therapy
Mundipharma Korea Ltd n=20
NCT03528577 COMPLETED
A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
Sun Pharmaceutical Industries Limited n=128
NCT02821416 COMPLETED
Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
AstraZeneca n=46
NCT03771040 COMPLETED
Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels
AB Science n=347
NCT02584257 COMPLETED
Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma
Lupin, Inc. n=217
NCT04051710 COMPLETED
Clinical Pharmacodynamic Bioequivalence Study of Beclomethasone Dipropionate 40 mcg INH
Aurobindo Pharma Ltd n=1,550
NCT04607629 COMPLETED
An Efficacy and Safety Study of Genolar® and Xolar® in the Persistent Atopic Bronchial Asthma
AO GENERIUM n=192
NCT03052517 TERMINATED
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment
Novartis Pharmaceuticals n=2,538
NCT03394508 COMPLETED
The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma
Karolinska Institutet n=30
NCT03133897 TERMINATED
Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study
Children's Hospital of Eastern Ontario n=20
NCT03394989 COMPLETED
BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients
Cipla Ltd. n=1,366
NCT03358147 COMPLETED
Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma
Pearl Therapeutics, Inc. n=1,077
NCT02571777 COMPLETED
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
Novartis Pharmaceuticals n=3,092
NCT03676413 COMPLETED
A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
Respirent Pharmaceuticals Co Ltd. n=451
NCT03184987 COMPLETED
A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma
GlaxoSmithKline n=111
NCT02555683 COMPLETED
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
Novartis Pharmaceuticals n=894
NCT02483975 COMPLETED
Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma
GlaxoSmithKline n=111
NCT01720069 COMPLETED
Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma
Vectura Limited n=197
NCT01472757 COMPLETED
Clinical Study to Evaluate the Efficacy of VR506 Using a New Inhaler for the Treatment of Asthma
Vectura Limited n=374
NCT03100825 COMPLETED
A Long-term Safety Study of QVM149 in Japanese Patients With Asthma
Novartis Pharmaceuticals n=96
NCT02554786 COMPLETED
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma
Novartis Pharmaceuticals n=2,216
NCT03100500 COMPLETED
A Long-term Safety Study of QMF149 in Japanese Participants With Asthma
Novartis Pharmaceuticals n=51
NCT02555371 COMPLETED
Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients
GlaxoSmithKline n=306
NCT03562949 TERMINATED
A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol
Amneal Ireland Limited n=761
NCT02135692 COMPLETED
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
GlaxoSmithKline n=339
NCT03014674 COMPLETED
A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug
GlaxoSmithKline n=246
NCT02495168 COMPLETED
Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants
Actavis Inc. n=1,714
NCT02224157 COMPLETED
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma
AstraZeneca n=4,215
NCT02149199 COMPLETED
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.
AstraZeneca n=3,850
NCT02869438 COMPLETED
A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation
AstraZeneca n=233
NCT02528214 COMPLETED
Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma
Sanofi n=210
NCT02902809 TERMINATED
A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
AstraZeneca n=28
NCT02258542 COMPLETED
A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA
AstraZeneca n=2,133
NCT02624505 COMPLETED
Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma
Cipla Ltd. n=110
NCT03835871 WITHDRAWN
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma
Adamis Pharmaceuticals Corporation
NCT03834012 WITHDRAWN
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma
Adamis Pharmaceuticals Corporation
NCT02853578 SUSPENDED
Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled
Ache Laboratorios Farmaceuticos S.A. n=80
NCT02496715 WITHDRAWN
Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics
Actavis Inc.
NCT01192360 COMPLETED
Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease
The Hospital for Sick Children n=16
NCT01419262 COMPLETED
DO IT Trial: Vitamin D Outcomes and Interventions In Toddlers
The Hospital for Sick Children n=703
NCT03505489 COMPLETED
The Effect of Deep Inhalation on Mannitol Responsiveness
University of Saskatchewan n=26
NCT03816267 COMPLETED
Salbutamol Administration by Nebulizer Versus Metered Dose Inhaler With Spacer in Asthma in Children
Suez Canal University n=60
NCT03376932 WITHDRAWN
Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma
GlaxoSmithKline
NCT02281357 COMPLETED
Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma
AstraZeneca n=140
NCT02725008 COMPLETED
Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation
Geoffrey W Jara-Almonte n=99
NCT01706198 COMPLETED
An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma
GlaxoSmithKline n=4,233
NCT03137784 COMPLETED
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
Novartis Pharmaceuticals n=148
NCT02446418 COMPLETED
A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma
GlaxoSmithKline n=423
NCT01967173 COMPLETED
Best African American Response to Asthma Drugs
Milton S. Hershey Medical Center n=574
NCT02918071 COMPLETED
Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home
AstraZeneca n=121
NCT00734318 COMPLETED
Study of FlutiForm® Versus Fluticasone Plus Formoterol in Adult Subjects With Severe Asthma
Mundipharma Research Limited n=1,667
NCT02814643 COMPLETED
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma
AstraZeneca n=103
NCT01511367 COMPLETED
Comparison of Flutiform, Fluticasone and Seretide in Treatment of Moderate to Severe Asthma in Paediatric Patients
Mundipharma Research Limited n=498
NCT01099722 COMPLETED
Assessment of the Efficacy and Safety of FlutiForm® pMDI 125/5 µg (2 Puffs Bid) Versus Symbicort® Turbohaler® 200/6 µg (2 Puffs Bid) in Adolescent and Adult Subjects With Moderate to Severe Persistent, Reversible Asthma
Mundipharma Research Limited n=261
NCT02414854 COMPLETED
Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)
Sanofi n=1,902
NCT02753712 COMPLETED
A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma
Mundipharma Research Limited n=105
NCT01687283 COMPLETED
Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma
GlaxoSmithKline n=316
NCT02161757 COMPLETED
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
AstraZeneca n=1,207
NCT02301975 COMPLETED
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma
GlaxoSmithKline n=1,526
NCT02281318 COMPLETED
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
GlaxoSmithKline n=556
NCT01842607 COMPLETED
A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects
GlaxoSmithKline n=651
NCT01691521 COMPLETED
Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma
GlaxoSmithKline n=580
NCT01460511 COMPLETED
Evaluation of Efficacy and Safety of E004 in Children With Asthma
Amphastar Pharmaceuticals, Inc. n=70
NCT02066129 COMPLETED
Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
Milton S. Hershey Medical Center n=254
NCT00565266 COMPLETED
Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)
Milton S. Hershey Medical Center n=210
NCT00675584 COMPLETED
CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)
Milton S. Hershey Medical Center n=278
NCT01687296 COMPLETED
Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma
GlaxoSmithKline n=261
NCT01658891 WITHDRAWN
Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children
Chiesi Farmaceutici S.p.A.
NCT02075255 COMPLETED
Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
AstraZeneca n=220
NCT02417961 COMPLETED
Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home
AstraZeneca n=162
NCT02194699 COMPLETED
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
AstraZeneca n=856
NCT02546869 WITHDRAWN
A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting
Hoffmann-La Roche
NCT00862394 COMPLETED
A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma
Chiesi Farmaceutici S.p.A. n=783
NCT02559791 COMPLETED
Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma
McMaster University n=10
NCT02049294 COMPLETED
Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis
McMaster University n=11
NCT01290874 COMPLETED
Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)
Brigham and Women's Hospital n=1,070
NCT02596321 COMPLETED
A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma
Abbott n=112
NCT01018186 COMPLETED
Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study
GlaxoSmithKline n=503
NCT01165138 COMPLETED
Study HZA106827: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
GlaxoSmithKline n=612
NCT01132430 COMPLETED
Motivational Interviewing for Medication Adherence in Asthma
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal n=50
NCT00953342 COMPLETED
Impact of Aerobic Exercise on Asthma Morbidity
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal n=66
NCT01686633 COMPLETED
An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.
GlaxoSmithKline n=1,040
NCT02230332 COMPLETED
Alendronate to Prevent Loss of Bronchoprotection in Asthma
Milton S. Hershey Medical Center n=78
NCT03372473 COMPLETED
Montelukast and Loratadine in Children With Asthma
Innovacion y Desarrollo de Estrategias en Salud n=80
NCT02502734 COMPLETED
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
GlaxoSmithKline n=60
NCT01159912 COMPLETED
Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents
GlaxoSmithKline n=350
NCT01181895 COMPLETED
Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
GlaxoSmithKline n=348
NCT02322775 COMPLETED
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
AstraZeneca n=211
NCT02594332 TERMINATED
Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study
Johannes Gutenberg University Mainz n=29
NCT01978119 COMPLETED
A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma
GlaxoSmithKline n=124
NCT02094937 COMPLETED
A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects
GlaxoSmithKline n=430
NCT01868061 COMPLETED
A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication
Hoffmann-La Roche n=1,068
NCT01867125 COMPLETED
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Hoffmann-La Roche n=1,081
NCT01875003 COMPLETED
A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Hoffmann-La Roche n=348
NCT01928771 COMPLETED
Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
AstraZeneca n=2,681
NCT02725242 COMPLETED
Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma
Hat Yai Medical Education Center n=77
NCT00642616 TERMINATED
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
Mannkind Corporation n=34
NCT02091986 COMPLETED
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
AstraZeneca n=882
NCT01345916 COMPLETED
Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients
Chiesi Farmaceutici S.p.A. n=932
NCT01522040 WITHDRAWN
Pilot Study of Magnesium Infusions in Pediatric Asthma
University of Louisville
NCT01475032 COMPLETED
Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children
Chiesi Farmaceutici S.p.A. n=638
NCT02097537 COMPLETED
Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma
Santen Pharmaceutical Co., Ltd. n=10
NCT01450774 COMPLETED
Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children
Chiesi Farmaceutici S.p.A. n=72
NCT01691508 COMPLETED
Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma
GlaxoSmithKline n=135
NCT01606306 COMPLETED
Individualized Therapy For Asthma in Toddlers
Milton S. Hershey Medical Center n=300
NCT01498679 COMPLETED
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.
GlaxoSmithKline n=311
NCT00783198 COMPLETED
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
ALK-Abelló A/S n=565
NCT01476904 COMPLETED
Safety Study in Adolescent and Adult Patients With Asthma
Amphastar Pharmaceuticals, Inc. n=208
NCT01433523 COMPLETED
House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma
ALK-Abelló A/S n=834
NCT01914757 COMPLETED
Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist
AstraZeneca n=2,508
NCT01147848 COMPLETED
HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents
GlaxoSmithKline n=810
NCT01086410 COMPLETED
Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis
GlaxoSmithKline n=185
NCT01606319 COMPLETED
Acetaminophen Versus Ibuprofen in Children With Asthma
Milton S. Hershey Medical Center n=300
NCT02322788 COMPLETED
Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3
AstraZeneca n=95
NCT01134042 COMPLETED
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
GlaxoSmithKline n=587
NCT01436071 COMPLETED
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma
GlaxoSmithKline n=248
NCT01244984 COMPLETED
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma
GlaxoSmithKline n=243
NCT01498653 COMPLETED
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry
GlaxoSmithKline n=313
NCT01436110 COMPLETED
Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma
GlaxoSmithKline n=351
NCT01431950 COMPLETED
Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents
GlaxoSmithKline n=238
NCT01272635 COMPLETED
Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.
Milton S. Hershey Medical Center n=607
NCT01444430 COMPLETED
A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents
AstraZeneca n=12,460
NCT01155700 COMPLETED
Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Omalizumab in Japanese Children (6 - 15 Years)
Novartis Pharmaceuticals n=51
NCT01328886 COMPLETED
Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children
Novartis Pharmaceuticals n=38
NCT02104674 COMPLETED
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
Hoffmann-La Roche n=313
NCT01634139 COMPLETED
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma
Boehringer Ingelheim n=403
NCT01508936 COMPLETED
Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=511
NCT01270464 COMPLETED
A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=315
NCT01290887 TERMINATED
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=1,052
NCT02734446 COMPLETED
To Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children
University of Campania Luigi Vanvitelli n=52
NCT02150499 TERMINATED
A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects
Sumitomo Pharma America, Inc. n=18
NCT02293265 COMPLETED
Cross-sectional Study for Identification and Description of Severe Asthma Patients
GlaxoSmithKline n=767
NCT01266434 COMPLETED
The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma
Mahidol University n=44
NCT01737905 COMPLETED
Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma
Amphastar Pharmaceuticals, Inc. n=28
NCT01357642 COMPLETED
Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
Amphastar Pharmaceuticals, Inc. n=373
NCT01634152 COMPLETED
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
Boehringer Ingelheim n=401
NCT01907763 TERMINATED
Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients
SK Chemicals Co., Ltd. n=194
NCT01976208 COMPLETED
Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma
Shanghai Zhangjiang Biotechnology Limited Company n=630
NCT01947946 TERMINATED
Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
AstraZeneca n=13
NCT02371993 COMPLETED
Asthma in the Elderly: A Study of Choline Supplementation
Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C. n=30
NCT01868113 COMPLETED
Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial
Makerere University n=1,010
NCT01698320 COMPLETED
Safety Study of Albuterol Spiromax® in Subjects With Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=364
NCT02308098 COMPLETED
To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product
Orion Corporation, Orion Pharma n=72
NCT01424813 COMPLETED
A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
Teva Branded Pharmaceutical Products R&D, Inc. n=158
NCT01747629 COMPLETED
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics
Teva Branded Pharmaceutical Products R&D, Inc. n=160
NCT01202084 COMPLETED
A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients
Eurofarma Laboratorios S.A. n=222
NCT01857323 COMPLETED
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
Teva Branded Pharmaceutical Products R&D, Inc. n=317
NCT01218009 TERMINATED
A Twelve Month Long Term Safety Study to Evaluate the Safety of Albuterol in a Dry Powder Inhaler With Both Repeated and as Needed Dosing
Teva Branded Pharmaceutical Products R&D, Inc. n=331
NCT00807183 COMPLETED
Indoor Woodsmoke PM and Asthma
National Institute of Environmental Health Sciences (NIEHS) n=122
NCT01316380 COMPLETED
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma
Boehringer Ingelheim n=465
NCT02127697 WITHDRAWN
Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma
Novartis Pharmaceuticals
NCT01453881 COMPLETED
Fine Particle pMDI Formoterol/Beclomethasone in Asthmatics With and Without Spacer: Comparative Efficacy Evaluation
Universidade Federal de Pernambuco n=45
NCT01202903 COMPLETED
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
Novartis Pharmaceuticals n=616
NCT02100267 COMPLETED
A Study to Evaluate Efficacy and Safety of Methacholine Chloride Challenge Test in Diagnosis of Adult Asthma
Sanwa Kagaku Kenkyusho Co., Ltd.
NCT01353755 COMPLETED
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
Allergopharma GmbH & Co. KG n=195
NCT01277523 COMPLETED
Efficacy and Safety of 2 Doses of Tiotropium Respimat Compared to Placebo in Adolescents With Severe Persistent Asthma
Boehringer Ingelheim n=392
NCT01730976 COMPLETED
Asthma in the Elderly: The Role of Vitamin D
Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C. n=30
NCT00776984 COMPLETED
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)
Boehringer Ingelheim n=453
NCT01257230 COMPLETED
Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma
Boehringer Ingelheim n=398
NCT00772538 COMPLETED
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
Boehringer Ingelheim n=459
NCT01248065 COMPLETED
Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma
Milton S. Hershey Medical Center n=408
NCT00809757 COMPLETED
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
Sumitomo Pharma America, Inc. n=197
NCT00935077 COMPLETED
A Collaborative Model to Improve Blood Pressure (BP) Control and Minimize Racial Disparities
University of Iowa n=1,441
NCT01340209 COMPLETED
Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma
Boehringer Ingelheim n=285
NCT01435902 WITHDRAWN
A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise
GlaxoSmithKline
NCT01172821 COMPLETED
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II
Boehringer Ingelheim n=1,032
NCT01172808 COMPLETED
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
Boehringer Ingelheim n=1,071
NCT00849095 COMPLETED
Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma
Università degli Studi di Ferrara n=860
NCT01360021 COMPLETED
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
AstraZeneca n=214
NCT00978315 COMPLETED
Trial of Vitamin D Supplementation in Asthma
Barts & The London NHS Trust n=250
NCT01795664 COMPLETED
Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients
FLUIDDA nv n=16
NCT01274325 COMPLETED
Comparison of Anti-inflammatory Effects of Seroflo and Seretide in Patients With Asthma
Mahidol University n=51
NCT00792337 COMPLETED
The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma
Mahidol University n=53
NCT00634517 TERMINATED
4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma
Amphastar Pharmaceuticals, Inc. n=48
NCT00634829 TERMINATED
Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction
Amphastar Pharmaceuticals, Inc. n=24
NCT00921401 COMPLETED
Improving the Quality of Asthma Care Using the Internet
Milton S. Hershey Medical Center n=408
NCT01095016 COMPLETED
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler and Berotec N® Metered Aerosol in Mild to Moderate Stable Asthma Patients
Taiwan Otsuka Pharm. Co., Ltd n=32
NCT00667992 COMPLETED
Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma
AstraZeneca n=99
NCT01096017 COMPLETED
To Investigate the Relative Efficacy of Terbutaline Turbuhaler® and Salbutamol Pressurized Metered Dose Inhaler (pMDI) a Single Blind Study
AstraZeneca n=24
NCT01676987 COMPLETED
Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma
Ache Laboratorios Farmaceuticos S.A. n=181
NCT00837967 COMPLETED
Study to Investigate the Safety and Efficacy of High Dose of Symbicort® SMART in Japanese Patients
AstraZeneca n=25
NCT01007149 COMPLETED
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
Novartis Pharmaceuticals n=79
NCT01079130 COMPLETED
Efficacy and Safety of Different Doses of Indacaterol
Novartis Pharmaceuticals n=511
NCT00747318 COMPLETED
A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005
SkyePharma AG n=280
NCT00855959 COMPLETED
Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients
AstraZeneca n=108
NCT01047657 COMPLETED
Effects of Weight Loss in Obese Difficult-to-treat Asthmatics
University of Sao Paulo General Hospital n=33
NCT00986323 COMPLETED
Efficacy Study of Temperature Controlled Laminar Airflow (TLA)-Treatment in Perennial Allergic Asthma
Airsonett AB n=312
NCT00649025 COMPLETED
A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults
SkyePharma AG n=438
NCT01076322 COMPLETED
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients
Taiwan Otsuka Pharm. Co., Ltd n=17
NCT01113489 COMPLETED
Assessment of Oxidative Stress Markers in the Upper and Lower Airways of Atopic Children Treated With Nebulized Beclomethasone
Fondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy n=32
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only